Literature DB >> 19907149

Mitochondrial iron metabolism and sideroblastic anemia.

Alex D Sheftel1, Des R Richardson, Josef Prchal, Prem Ponka.   

Abstract

Sideroblastic anemias are a heterogeneous group of disorders, characterized by mitochondrial iron overload in developing red blood cells. The unifying characteristic of all sideroblastic anemias is the ring sideroblast, which is a pathological erythroid precursor containing excessive deposits of non-heme iron in mitochondria with perinuclear distribution creating a ring appearance. Sideroblastic anemias may be hereditary or acquired. Hereditary sideroblastic anemias are caused by defects in genes present on the X chromosome (mutations in the ALAS2, ABCB7, or GRLX5 gene), genes on autosomal chromosomes, or mitochondrial genes. Acquired sideroblastic anemias are either primary (refractory anemia with ring sideroblasts, RARS, representing one subtype of the myelodysplastic syndrome) or secondary due to some drugs, toxins, copper deficiency, or chronic neoplastic disease. The pathogenesis of mitochondrial iron loading in developing erythroblasts is diverse. Ring sideroblasts can develop as a result of a heme synthesis defect in erythroblasts (ALAS2 mutations), a defect in iron-sulfur cluster assembly, iron-sulfur protein precursor release from mitochondria (ABCB7 mutations), or by a defect in intracellular iron metabolism in erythroid cells (e.g. RARS). Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19907149     DOI: 10.1159/000243796

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  16 in total

Review 1.  Cellular and mitochondrial iron homeostasis in vertebrates.

Authors:  Caiyong Chen; Barry H Paw
Journal:  Biochim Biophys Acta       Date:  2012-01-18

Review 2.  The long history of iron in the Universe and in health and disease.

Authors:  Alex D Sheftel; Anne B Mason; Prem Ponka
Journal:  Biochim Biophys Acta       Date:  2011-08-09

Review 3.  Control of intracellular heme levels: heme transporters and heme oxygenases.

Authors:  Anwar A Khan; John G Quigley
Journal:  Biochim Biophys Acta       Date:  2011-01-14

4.  Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.

Authors:  Gerbrig Berger; Mylene Gerritsen; Guoqiang Yi; Theresia N Koorenhof-Scheele; Leonie I Kroeze; Marian Stevens-Kroef; Kenichi Yoshida; Yuichi Shiraishi; Eva van den Berg; Hein Schepers; Geert Huls; André B Mulder; Seishi Ogawa; Joost H A Martens; Joop H Jansen; Edo Vellenga
Journal:  Blood Adv       Date:  2019-10-22

Review 5.  Mechanisms of mammalian iron homeostasis.

Authors:  Kostas Pantopoulos; Suheel Kumar Porwal; Alan Tartakoff; L Devireddy
Journal:  Biochemistry       Date:  2012-07-09       Impact factor: 3.162

Review 6.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.

Authors:  V Visconte; H Makishima; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2012-05-15       Impact factor: 11.528

7.  Mitochondria represent another locale for the divalent metal transporter 1 (DMT1).

Authors:  Natascha A Wolff; Laura M Garrick; Lin Zhao; Michael D Garrick; Frank Thévenod
Journal:  Channels (Austin)       Date:  2014       Impact factor: 2.581

8.  Iron Loading and Overloading due to Ineffective Erythropoiesis.

Authors:  Toshihiko Tanno; Jeffery L Miller
Journal:  Adv Hematol       Date:  2010-05-11

Review 9.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

10.  Haematological abnormalities in mitochondrial disorders.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Singapore Med J       Date:  2015-07       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.